Market Lifecycle Stage
The global messenger RNA market is currently in the growth stage of its lifecycle, driven by the rapid success of mRNA vaccines, particularly for COVID-19, which has expanded its applications to other infectious diseases and therapeutic areas such as cancer and genetic disorders. This growth is supported by significant investments from both public and private sectors, accelerating research and development in mRNA technology. The market is witnessing increased interest from pharmaceutical companies and biotechnology firms aiming to diversify mRNA applications beyond vaccines into gene therapies and cancer immunotherapies. However, challenges such as high production costs, delivery system optimization, and long-term safety concerns still exist. As research progresses and regulatory bodies fast-track approvals, the market is expected to continue to grow. Over the next few years, mRNA-based therapeutics will likely become a critical part of the global healthcare landscape, making this a dynamic and rapidly evolving market.
Impact
Increasing demand for messenger RNA therapies is anticipated to support the growth of the global messenger RNA market during the forecast period 2025-2035.
The global messenger RNA market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.
Market Segmentation:
Segmentation 1: by Application
Oncology
Infectious Diseases
Rare Genetic Diseases
Respiratory Diseases
Other Applications
Segmentation 2: by Region
North America
Europe
Asia-Pacific
Rest-of-the-World
North America is expected to dominate the global messenger RNA market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global messenger RNA market.
Recent Developments
Regulatory Activities: In April 2025, the U.S. FDA granted fast-track designation to Arcturus Therapeutics Holdings Inc. for its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304.
Partnerships: In January 2025, Etherna Immunotherapies NV announced a strategic collaboration with Dropshot Therapeutics. This partnership combines the advanced platforms of both companies to accelerate the development of RNA-based therapeutics and facilitate the creation of multiple new drug candidates across various indications.
Partnerships: In May 2024, Achilles Therapeutics announced a research collaboration with Arcturus Therapeutics to explore second-generation personalized mRNA cancer vaccines. This partnership aims to leverage both companies' expertise in mRNA technology to develop innovative, personalized cancer treatments.
Demand – Drivers and Limitations
The following are the drivers for the global messenger RNA market:
Advancements in mRNA Technology
Rising Demand for mRNA Vaccines
Growing Applications in Cancer Therapy
The global messenger RNA market is expected to face some limitations, too, due to the following challenges:
High Cost of mRNA Production
How Can This Report Add Value to an Organization?
Product/Innovation Strategy:Product launches and innovations in the global messenger RNA market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Arcturus Therapeutics Holdings Inc., Etherna Immunotherapies NV, and Dropshot Therapeutics, have been involved in the development of therapies for messenger RNA.
Competitive Strategy:Enterprises led by market leaders in the global messenger RNA market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.
Some of the prominent names established in this market are:
Pfizer
GlaxoSmithKline plc
Arcturus Therapeutics, Inc.
AstraZeneca
Beam Therapeutics Inc.
ModernaTX, Inc.
Oncotelic Inc.
SK Bioscience Co., Ltd.
Sangamo Therapeutics
Sanofi
CureVac N.V.
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- Executive Summary
- Scope of Study
- 1. Global Messenger RNA Market: Market Outlook
- 1.1 Industry Outlook
- 1.1.1 Market Overview and Ecosystem
- 1.1.2 Market Trends
- 1.1.3 Clinical Trials
- 1.1.3.1 By Phase
- 1.1.3.2 By Sponsor Type
- 1.1.4 Regulatory Landscape / Compliance
- 1.1.4.1 Legal Requirement and Framework in the U.S.
- 1.1.4.2 Legal Requirement and Framework in the E.U.
- 1.1.4.3 Legal Requirement and Framework in Asia-Pacific
- 1.1.4.4 Legal Requirement and Framework in Rest-of-the-World
- 1.2 Market Dynamics
- 1.2.1 Impact Analysis
- 1.2.2 Market Drivers
- 1.2.3 Market Restraints
- 1.2.4 Market Opportunities
- 2. Global Messenger RNA Market (By Application), $Million, 2023-2035
- 2.1 Overview
- 2.2 Oncology
- 2.3 Infectious Diseases
- 2.4 Rare Genetic Diseases
- 2.5 Respiratory Diseases
- 2.6 Other Applications
- 3. Global Messenger RNA Market (By Region), $Million, 2023-2035
- 3.1 North America
- 3.1.1 Key Findings
- 3.1.2 Market Dynamics
- 3.1.3 Market Sizing and Forecast
- 3.1.3.1 North America Messenger RNA Market (by Country)
- 3.1.3.1.1 U.S.
- 3.1.3.1.2 Canada
- 3.2 Europe
- 3.2.1 Key Findings
- 3.2.2 Market Dynamics
- 3.2.3 Market Sizing and Forecast
- 3.2.3.1 Europe Messenger RNA Market (by Country)
- 3.2.3.1.1 U.K.
- 3.2.3.1.2 Germany
- 3.2.3.1.3 France
- 3.2.3.1.4 Italy
- 3.2.3.1.5 Spain
- 3.2.3.1.6 Rest-of-Europe
- 3.3 Asia-Pacific
- 3.3.1 Key Findings
- 3.3.2 Market Dynamics
- 3.3.3 Market Sizing and Forecast
- 3.3.3.1 Asia-Pacific Messenger RNA Market (by Country)
- 3.3.3.1.1 Japan
- 3.3.3.1.2 China
- 3.3.3.1.3 Rest-of-Asia-Pacific
- 3.4 Rest-of-the-World
- 3.4.1 Key Findings
- 3.4.2 Market Dynamics
- 3.4.3 Market Sizing and Forecast
- 4. Global Messenger RNA Market - Competitive Benchmarking and Company Profiles
- 4.1 Competitive Landscape
- 4.1.1 Key Strategies and Developments by Company
- 4.1.1.1 Funding Activities
- 4.1.1.2 Mergers and Acquisitions
- 4.1.1.3 Regulatory Approvals
- 4.1.1.4 Partnerships, Collaborations and Business Expansions
- 4.1.2 Key Developments Analysis
- 4.2 Company Profiles
- 4.2.1 Arcturus Therapeutics, Inc.
- 4.2.1.1 Company Overview
- 4.2.1.2 Product Portfolio
- 4.2.1.3 Target Customers/End Users
- 4.2.1.4 Analyst View
- 4.2.2 ModernaTX, Inc.
- 4.2.2.1 Company Overview
- 4.2.2.2 Product Portfolio
- 4.2.2.3 Target Customers/End Users
- 4.2.2.4 Analyst View
- 4.2.3 Beam Therapeutics Inc.
- 4.2.3.1 Company Overview
- 4.2.3.2 Product Portfolio
- 4.2.3.3 Target Customers/End Users
- 4.2.3.4 Analyst View
- 4.2.4 AstraZeneca
- 4.2.4.1 Company Overview
- 4.2.4.2 Product Portfolio
- 4.2.4.3 Target Customers/End Users
- 4.2.4.4 Analyst View
- 4.2.5 SK Bioscience Co., Ltd.
- 4.2.5.1 Company Overview
- 4.2.5.2 Product Portfolio
- 4.2.5.3 Target Customers/End Users
- 4.2.5.4 Analyst View
- 4.2.6 Oncotelic Inc.
- 4.2.6.1 Company Overview
- 4.2.6.2 Product Portfolio
- 4.2.6.3 Target Customers/End Users
- 4.2.6.4 Analyst View
- 4.2.7 Sanofi
- 4.2.7.1 Company Overview
- 4.2.7.2 Product Portfolio
- 4.2.7.3 Target Customers/End Users
- 4.2.7.4 Analyst View
- 4.2.8 Sangamo Therapeutics
- 4.2.8.1 Company Overview
- 4.2.8.2 Product Portfolio
- 4.2.8.3 Target Customers/End Users
- 4.2.8.4 Analyst View
- 4.2.9 Pfizer
- 4.2.9.1 Company Overview
- 4.2.9.2 Product Portfolio
- 4.2.9.3 Target Customers/End Users
- 4.2.9.4 Analyst View
- 4.2.10 CureVac N.V.
- 4.2.10.1 Company Overview
- 4.2.10.2 Product Portfolio
- 4.2.10.3 Target Customers/End Users
- 4.2.10.4 Analyst View
- 4.2.11 GlaxoSmithKline plc
- 4.2.11.1 Company Overview
- 4.2.11.2 Product Portfolio
- 4.2.11.3 Target Customers/End Users
- 4.2.11.4 Analyst View
- 5. Research Methodology
- List of Figures
- Figure: Global Messenger RNA Market, Market Overview
- Figure: Global Messenger RNA Market Coverage
- Figure: Global Messenger RNA Market Key Trends, Impact Analysis, 2023-2035
- Figure: Global Messenger RNA Market, Competitive Landscape, January 2022-April 2025
- List of Tables
- Table: Global Messenger RNA Market, Regulatory Scenario
- Table: Global Messenger RNA Market Dynamics, Impact Analysis
- Table: Global Messenger RNA Market (by Application), $Million, 2023-2035
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook